- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02734277
Estudo de Extensão de Diabetes Tipo 1 (T1DES)
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
- follow participants to determine how long they continue to produce insulin, and
- will also assess how changes in the immune system over time relate to the ability to produce insulin.
This information could help design better therapies for type 1 diabetes in the future.
Visão geral do estudo
Status
Condições
Descrição detalhada
Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:
- Overall health assessments
- Blood and urine collections
- Mixed meal tolerance test (MMTTs) for certain participants, per protocol.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- Recrutamento
- UCSF School of Medicine
-
Contato:
- Rebecca Wesch
- Número de telefone: 415-476-5984
- E-mail: rebecca.wesch@ucsf.edu
-
Investigador principal:
- Stephen Gitelman, MD
-
Stanford, California, Estados Unidos, 94305
- Recrutamento
- Stanford University
-
Contato:
- Trudy Esrey
- Número de telefone: 650-498-4450
- E-mail: tesrey@stanford.edu
-
Investigador principal:
- Darrell Wilson, MD
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
Investigador principal:
- Peter Gottlieb, MD
-
Contato:
- Mara Kinney
- Número de telefone: (303) 724-8272
- E-mail: MARA.KINNEY@ucdenver.edu
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06519
- Concluído
- Yale University
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Retirado
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Recrutamento
- Indiana University Riley Hospital for Children
-
Contato:
- Ellie Ryan
- Número de telefone: 317-278-7037
- E-mail: elmryan@iu.edu
-
Contato:
- Maria Spall
- Número de telefone: 317-278-7034
- E-mail: malnicho@iu.edu
-
Investigador principal:
- Linda DiMeglio, MD, MPH
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa Health Care Division of Pediatric Endocrinology
-
Contato:
- Joanne Cabbage
- Número de telefone: 319-356-4035
- E-mail: joanne-cabbage@uiowa.edu
-
Investigador principal:
- Michael Tansey, MD
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Joslin Diabetes Center
-
Contato:
- Site Public Contact
- Número de telefone: 888-813-8669
- E-mail: T1DTrials@joslin.harvard.edu
-
Investigador principal:
- Jason Gaglia, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55454
- Recrutamento
- University of Minnesota
-
Contato:
- Anne Street
- Número de telefone: 612-625-9709
- E-mail: stree065@umn.edu
-
Investigador principal:
- Antoinette Moran, MD
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Concluído
- Children's Mercy Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Concluído
- Sanford Research
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Recrutamento
- Benaroya Research Institute
-
Investigador principal:
- Sandra Lord, MD
-
Contato:
- Katie Bennett
- Número de telefone: (206) 341-8945
- E-mail: kbennett@benaroyaresearch.org
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.
Descrição
Inclusion Criteria:
- Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
- Ability to sign informed consent/assent (as applicable for children).
Exclusion Criteria:
- Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
- Inability to comply with the study visit schedule and required assessments.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Group 1: Detectable C-peptide by MMTT
Participants with detectable C-peptide at their:
Detectable C-peptide is defined as a value above the lower limit of detection. |
|
Group 2:Undetectable C-peptide by MMTT
Participants without detectable C-peptide at their:
Undetectable C-peptide is defined as a value below the lower limit of detection. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
Prazo: Baseline (Visit 0) to Month 60 (Year 5)
|
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL. |
Baseline (Visit 0) to Month 60 (Year 5)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Insulin Use in Units per Kilogram Body Weight Per Day
Prazo: Baseline (Visit 0) to Month 60 (Year 5)
|
The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Change in HbA1C
Prazo: Baseline (Visit 0) to Month 60 (Year 5)
|
Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Count of Participant-Reported Major Hypoglycemic Events
Prazo: Baseline (Visit 0) to Month 60 (Year 5)
|
Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Time to Undetectable C-Peptide
Prazo: Baseline (Visit 0) to Month 60 (Year 5)
|
To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
Prazo: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
Prazo: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Cadeira de estudo: Linda A. DiMeglio, MD, MPH,MA, Riley Hospital for Children at Indiana University Health
Publicações e links úteis
Publicações Gerais
- Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.
- Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.
- Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- DAIT ITN066AI
- NIAID CRMS ID#: 20722 (Outro identificador: DAIT NIAID)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.
Prazo de Compartilhamento de IPD
After completion of the study.
Critérios de acesso de compartilhamento IPD
Will be available to the public.
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .